Rockefeller Capital Management L.P. Reduces Holdings in Illumina, Inc. $ILMN

Posted by Francis Steltz on Jun 27th, 2026

Rockefeller Capital Management L.P. lowered its position in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 80.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 49,366 shares of the life sciences company’s stock after selling 206,985 shares during the period. Rockefeller Capital Management L.P.’s holdings in Illumina were worth $6,475,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. JPMorgan Chase & Co. boosted its holdings in shares of Illumina by 17.5% in the third quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock valued at $79,081,000 after acquiring an additional 124,246 shares during the period. Elo Mutual Pension Insurance Co acquired a new position in shares of Illumina in the 3rd quarter valued at $2,319,000. Nordea Investment Management AB increased its holdings in shares of Illumina by 2,792.2% in the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock valued at $124,145,000 after acquiring an additional 911,843 shares during the period. Capital World Investors raised its position in Illumina by 20.0% in the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock valued at $1,897,178,000 after purchasing an additional 3,331,542 shares during the last quarter. Finally, Neo Ivy Capital Management purchased a new stake in Illumina in the 3rd quarter valued at $1,827,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Illumina

In other news, SVP Patricia Leckman sold 783 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the sale, the senior vice president directly owned 21,259 shares of the company’s stock, valued at $3,456,500.81. This trade represents a 3.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 1,500 shares of Illumina stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $150.10, for a total value of $225,150.00. Following the completion of the sale, the chief accounting officer owned 14,946 shares in the company, valued at approximately $2,243,394.60. This trade represents a 9.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,003,769 shares of company stock worth $155,710,908 in the last three months. 2.90% of the stock is currently owned by corporate insiders.

Illumina Stock Down 0.6%

Shares of NASDAQ:ILMN opened at $176.55 on Friday. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $182.84. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The firm’s 50-day simple moving average is $149.62 and its 200-day simple moving average is $137.66. The company has a market cap of $26.71 billion, a price-to-earnings ratio of 32.10, a PEG ratio of 3.32 and a beta of 1.50.

Illumina (NASDAQ:ILMN – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.10. The firm had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 5.21 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ILMN has been the topic of several research reports. Evercore reissued an “outperform” rating on shares of Illumina in a research report on Friday, May 1st. Barclays upped their target price on shares of Illumina from $122.00 to $145.00 and gave the company an “underweight” rating in a report on Wednesday. Citigroup increased their target price on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research note on Monday, May 4th. JPMorgan Chase & Co. raised Illumina from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $125.00 to $185.00 in a report on Wednesday, June 10th. Finally, Royal Bank Of Canada started coverage on Illumina in a research report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price target on the stock. Eight investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $146.00.

Read Our Latest Research Report on ILMN

About Illumina

(Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.